Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 14/20 | 0.58 |
| ▸ | PTGS1 | P23219 | 9/20 | 0.58 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.57 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | CA4 | P22748 | 1/20 | 0.51 |
| ▸ | CA9 | Q16790 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27500961 | 0.89 | PTGS2 (0.60) | PTGS2PTGS1CHRNA7CA1CA2 | |
| SCHEMBL8691453 | 0.87 | PTGS2 (0.58) | PTGS2PTGS1PDPK1CA1CA2 | |
| SCHEMBL6260416 | 0.79 | PTGS2 (0.60) | PTGS2PTGS1PDPK1CHRNA7SMN1; SMN2 | |
| SCHEMBL6344415 | 0.78 | PTGS2 (0.73) | PTGS2PTGS1PDPK1CHRNA7SMN1; SMN2 | |
| SCHEMBL5698697 | 0.77 | PTGS2 (0.88) | PTGS2PTGS1PDPK1CHRNA7SMN1; SMN2 | |
| SCHEMBL5698671 | 0.76 | PTGS2 (0.76) | PTGS2PTGS1PDPK1CHRNA7SMN1; SMN2 | |
| SCHEMBL5698711 | 0.76 | PTGS2 (0.70) | PTGS2PTGS1PDPK1CHRNA7SMN1; SMN2 | |
| SCHEMBL5698606 | 0.76 | PTGS2 (0.76) | PTGS2PTGS1PDPK1CHRNA7SMN1; SMN2 | |
| SCHEMBL6350845 | 0.76 | PTGS2 (0.73) | PTGS2PTGS1PDPK1CHRNA7SMN1; SMN2 | |
| SCHEMBL6341597 | 0.76 | PTGS2 (0.70) | PTGS2PTGS1PDPK1CHRNA7SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2421852-B9 | HETEROAROMATIC AND AROMATIC PIPERAZINYL AZETIDINYL AMIDES AS MONOACYLGLYCEROL LIPASE INHIBITOR | JANSSEN PHARMACEUTICA NV (BE) | 2015-07-01 | — | — | EP | claimed |
| CN-102548983-B | Heteroaromatic and aromatic piperazinyl azetidinyl amides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA NV | 2014-09-17 | — | — | CN | claimed |
| US-8815839-B2 | Heteroaromatic and aromatic piperazinyl azetidinyl amides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2014-08-26 | — | — | US | claimed |
| EP-2421852-B1 | HETEROAROMATIC AND AROMATIC PIPERAZINYL AZETIDINYL AMIDES AS MONOACYLGLYCEROL LIPASE INHIBITOR | JANSSEN PHARMACEUTICA NV (BE) | 2014-05-21 | — | — | EP | claimed |
| US-20130184251-A1 | HETEROAROMATIC AND AROMATIC PIPERAZINYL AZETIDINYL AMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA, NV (BE) | 2013-07-18 | — | — | US | claimed |
| US-8415341-B2 | Heteroaromatic and aromatic piperazinyl azetidinyl amides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2013-04-09 | — | — | US | claimed |
| CN-102548983-A | Heteroaromatic and aromatic piperazinyl azetidinyl amides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA NV | 2012-07-04 | — | — | CN | claimed |
| EP-2421852-A1 | HETEROAROMATIC AND AROMATIC PIPERAZINYL AZETIDINYL AMIDES AS MONOACYLGLYCEROL LIPASE INHIBITOR | Janssen Pharmaceutica N.V. (BE) | 2012-02-29 | — | — | EP | claimed |
| US-20100324015-A1 | HETEROAROMATIC AND AROMATIC PIPERAZINYL AZETIDINYL AMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-23 | — | — | US | claimed |
| WO-2010124121-A1 | HETEROAROMATIC AND AROMATIC PIPERAZINYL AZETIDINYL AMIDES AS MONOACYLGLYCEROL LIPASE INHIBITOR | JANSEN PHARMACEUTICA NV (BE) | 2010-10-28 | — | — | WO | claimed |
| US-20060122184-A1 | Cyanomethyl derivatives as cysteine protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2006-06-08 | — | — | US | claimed |
| US-20050288336-A1 | Cysteine protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2005-12-29 | — | — | US | claimed |
| EP-1569954-A1 | CYANOMETHYL DERIVATIVES AS CYSTEINE PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2005-09-07 | — | — | EP | claimed |
| EP-1503997-A1 | CYSTEINE PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2005-02-09 | — | — | EP | claimed |
| WO-2004052921-A1 | CYANOMETHYL DERIVATIVES AS CYSTEINE PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2004-06-24 | — | — | WO | claimed |
| WO-2003097617-A1 | CYSTEINE PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2003-11-27 | — | — | WO | claimed |
| EP-2421852-B9 | HETEROAROMATIC AND AROMATIC PIPERAZINYL AZETIDINYL AMIDES AS MONOACYLGLYCEROL LIPASE INHIBITOR | JANSSEN PHARMACEUTICA NV (BE) | 2015-07-01 | — | — | EP | disclosed |
| CN-102548983-B | Heteroaromatic and aromatic piperazinyl azetidinyl amides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA NV | 2014-09-17 | — | — | CN | disclosed |
| WO-2004000838-A1 | PEPTIDIC COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2003-12-31 | — | — | WO | disclosed |
| WO-2003097617-A1 | CYSTEINE PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2003-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324015-A1 | HETEROAROMATIC AND AROMATIC PIPERAZINYL AZETIDINYL AMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | MGLL, PNLIP, LIPC | PTGS2 861/4885PTGS1 1010/4885PDPK1 1318/4885 |
| US-20130184251-A1 | HETEROAROMATIC AND AROMATIC PIPERAZINYL AZETIDINYL AMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | MGLL, PNLIP, LIPC | PTGS2 861/4885PTGS1 1010/4885PDPK1 1318/4885 |
| US-20060122184-A1 | Cyanomethyl derivatives as cysteine protease inhibitors | CTSF, CTSB, CTSK | PTGS2 1704/4885PTGS1 1189/4885PDPK1 2724/4885 |
| US-20050288336-A1 | Cysteine protease inhibitors | CTSF, CTSS, CTSB | PTGS2 1474/4885PTGS1 973/4885PDPK1 2325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.